Business Strategy & Financial Performance - Zymeworks is transitioning to a revenue-generating organization with in-house R&D capabilities, focusing on royalty streams and strategic capital allocation for shareholder returns[6] - The company reported $103 million in revenues for 2025 as of September 30, 2025[31] - Zymeworks anticipates up to $440 million in near-term milestones from global GEA approvals for Ziihera[20, 31] - A $125 million share repurchase plan has been announced[4, 31] - Existing cash resources are expected to fund operations beyond 2028, assuming full execution of the share repurchase plan and anticipated regulatory milestone payments[2, 31, 82] Pipeline & Partnerships - Zymeworks received a $25 million regulatory milestone payment from Jazz for FDA approval of Ziihera for HER2+ (IHC 3+) BTC[4] - The company also received a $20 million milestone payment from BeOne for NMPA conditional approval of Ziihera for BTC[4] - Zymeworks recognized $25.2 million in partnership milestone payments[4] - Zymeworks has potential future milestone payments of up to $434 million from one partner and up to $1.1 billion from another, plus tiered royalties[22] Clinical Development - Initial clinical data from the Phase 1 trial of ZW191 showed a 64% overall response rate in gynecological cancers at doses ≥6.4mg/kg[42, 49] - ZW251, an ADC targeting GPC3, is in Phase 1 clinical trials for hepatocellular carcinoma (HCC)[4, 55]

Financial Performance & Fleet Overview - Navios Maritime Partners L.P. reported a vessel value of $6.3 billion and net vessel equity value of $3.8 billion[7] - The company's fleet consists of 171 vessels, including 65 dry bulk vessels (8.6 million dwt), 51 containerships (287,243 TEU), and 55 tankers (6.4 million dwt)[6] - The average age of the fleet is approximately 9.7 years, which is younger than the industry average of 13.5 years[7] - Adjusted EBITDA for Q3 2025 LTM was $702 million, with available liquidity of $412 million, including $382 million in cash[7] Contracted Revenue & Chartering Strategy - The company has $3.7 billion in contracted revenue[7] - Contracted revenue is diversified across segments, with containerships accounting for 59% ($2.2 billion), tankers for 35% ($1.3 billion), and dry bulk for 6% ($0.2 billion)[43] - For Q4 2025E, 88% of available days are fixed at an average net daily rate of $24,871[107] Capital Allocation & Risk Management - The company is focused on chartering, allocating capital, and strengthening the balance sheet[9] - Key balance sheet targets include maintaining a net Loan-to-Value (LTV) and minimum cash per vessel[10] - The company has a risk management culture with continuous risk assessment and monitoring[12] Fleet Modernization & Expansion - The company is modernizing its fleet through a $1.9 billion newbuilding program, including $0.9 billion for containerships and $1.0 billion for tankers[38] - Sales YTD 2025 include $71.3 million gross proceeds from dry bulk vessels, $84.0 million from containerships, and $80.6 million from tankers[38] Return of Capital to Unitholders - The company has returned $42.2 million to unitholders YTD 2025, including $4.5 million in dividends and $37.7 million in common unit repurchases[17] - A $100 million common unit repurchase program is in place[18] Industry Outlook - The dry bulk shipping market plays a crucial role in global trade, with demand driven by worldwide economic growth[74] - The tanker fleet is aging rapidly, with the orderbook remaining muted at 16% of the sailing fleet[82] - The container market has seen significant ordering activity in larger sizes, while Navios is mainly exposed to sub 10,000 TEU size segments with lower orderbooks[101]

Transaction Overview - AkzoNobel and Axalta will combine in an all-stock merger of equals[21] - Axalta shareholders will receive 06539 shares of AkzoNobel common shares for each Axalta common share owned[21] - AkzoNobel expects to pay a special cash dividend to AkzoNobel shareholders equal to €25 billion minus regular dividends in 2026[21] - Pro forma ownership will be 55% AkzoNobel shareholders and 45% Axalta shareholders[21] Financial Benefits - The combination is expected to create ~$600 million in actionable cost and operational synergies[20, 39, 40] - The combined company's 2024A revenue is $169 billion[29] - The combined company's adjusted EBITDA is $33 billion, with a margin of ~195%[48] - The combined company's adjusted free cash flow is $15 billion[48] Strategic Advantages - The merger creates a top-tier portfolio with leading positions across key end-markets and globally recognized brands[20] - The combined company will have extensive scale, bringing global capabilities to local customers[20, 31] - The combined company will have a cutting-edge R&D and innovation platform, with ~$400 million in combined annual R&D spend[20, 34]

2028 Targets - Amundi aims for an adjusted EPS greater than €7 in 2028[15] - The company targets a cost-to-income ratio of less than 56% by 2028[15] - Amundi plans to maintain a payout ratio of at least 65% over the period of 2025-2028[13, 15] - The company is targeting +€300 billion in cumulated net inflows from 2025-2028 on growth priorities[15] Strategic Priorities - Amundi intends to accelerate diversification, focusing on high-potential segments like retirement and digital distribution[32, 35, 36] - The company aims to expand its global footprint, particularly in Asia, with a target of +€150 billion in net inflows from 2025-2028[32, 37, 38] - Amundi plans to invest in private assets and ETFs, differentiate and optimize active investment strategies, and lead in responsible investment[32, 40, 41] - The company aims to conquer through digitalization and technology, seeking to double its FY 2028 revenues compared to 2024, with a 2024 baseline of approximately €95 million[32, 42, 43] ICG Partnership - Amundi has formed a major partnership with ICG in private assets, expecting a return on investment of ≥10% within 3 years and an EPS accretion of approximately 5% in 2028[44, 56, 57] - ICG has $123 billion in AuM as of March 2025, which is a x2 growth from March 2021 with $56 billion[50] ETF Business - Amundi is the 1 European ETF provider, with +€55 billion in net inflows in 2025[98] - Amundi's ETF & Indexing AuM reached €314 billion in September 2025, compared to €190 billion in 2021, representing a x1.6 increase[98] - Amundi plans to launch +50 new ETFs by 2028[104]

Investor Presentation November 2022 Fourth Quarter Fiscal Year 2025 Supplemental Presentation November 18, 2025 Cautionary Statement Regarding Forward-Looking Statements Certain matters discussed in this presentation and the accompanying oral presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made based on known events and circumstances at the time of presentation, and as such, are subject to uncertaint ...

Supplemental Information Q4 FISCAL YEAR 2025 1 Revenue Composition(1) | ($ in thousands) | | | | | | | | | Quarter Ended | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | September 30, | | | | | | December 31, | | September 30, | | | | | | December 31, | | | | 2025 | | June 30, 2025 | | March 31, 2025 | | 2024 | | 2024 | | June 30, 2024 | | March 31, 2024 | | 2023 | | Software and related service revenue | | | | | | | | | | | | | | ...

Transaction Overview - AkzoNobel and Axalta will combine in an all-stock merger, with Axalta shareholders receiving 0.6539 shares of AkzoNobel for each Axalta share[31] - AkzoNobel expects to pay a special cash dividend to its shareholders equal to €2.5 billion minus regular dividends in 2026 prior to completion[31] - Pro forma ownership will be 55% AkzoNobel shareholders and 45% Axalta shareholders[31] - The transaction is expected to close in late 2026 to early 2027, pending approvals[31] Financial Highlights - The combination aims to create ~$600 million in cost and operational synergies[28] - The combined company's 2024A revenue is $16.9 billion, with $11.6 billion from AkzoNobel and $5.3 billion from Axalta[44, 67] - The combined adjusted EBITDA for 2024A is $3.3 billion, including synergies, with a margin of approximately 19.5%[67] - Adjusted Free Cash Flow is projected at $1.5 billion, including synergies[67] Strategic Benefits - The merger creates a top-tier portfolio with leading positions in key end-markets and globally recognized brands[28] - The combined company will have extensive scale, bringing global capabilities to local customers[28] - The combined R&D investment is approximately $400 million annually, representing about 2.5% of sales[52] - The combined company will have a balanced geographical revenue split, with 43% from EMEA, 24% from APAC, 23% from North America, and 10% from Latin America[48]

Financial Performance - The company's Q2 FY26 net sales reached $1.292 billion, a 34% increase[46] - Adjusted EBITDA for Q2 FY26 was $330 million, up 25%[46] - The adjusted EBITDA margin was 25.5%, a decrease of 190 basis points[46] - Year-to-date free cash flow was $58 million, a 58% decrease[46] Segment Performance - Siding & Trim (S&T) net sales were $696 million, reflecting a 3% organic decrease[55] - Deck, Rail & Accessories (DR&A) net sales were $256 million, up 6%[61] - Australia & New Zealand (ANZ) sales decreased by low-single digits (LSD%) in local currency to $148 million[63] - Europe net sales increased by low-double digits (LDD%) in local currency to $138 million[67] AZEK Integration and Synergies - The company is on track to achieve $125 million of cost synergies[37] - The company expects to exit FY26 annualizing $60 million+ of cost synergies[39] - The company anticipates over $500 million of commercial synergies through material conversion[41, 44]

Amer Sports Third Quarter 2025 FORWARD LOOKING STATEMENTS This presentation contains statements that constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "anticipate," "believe," "may," "will," "expect," "coul ...

Financial Performance - Medtronic reported a strong Q2 FY26 with 6.6% reported revenue growth and 5.5% organic revenue growth[17, 22] - Adjusted diluted EPS grew by 8% year-over-year[13, 20] - The company is raising FY26 revenue guidance by 50 bps to 5.5% and EPS guidance to $5.62-$5.66[13] - Adjusted gross margin expanded by 70 bps due to continued COGS efficiency program execution[15, 22] - The company is expecting ~$185 million tariff impact to COGS[54] Segment Performance - Cardiovascular segment showed strong performance with 9.3% organic growth[15, 21] - Cardiac Ablation Solutions (CAS) grew by 71% year-over-year, with 128% US growth[15, 39, 40] - Neuroscience segment grew by 3.9% organically[21] - Diabetes segment grew by 7.1% organically[21] - Medical Surgical segment grew by 1.3% organically[21] Strategic Initiatives - Medtronic is progressing toward Diabetes business separation by the end of CY26, with a preferred path of IPO and split-off[15, 47] - The company is increasing investments in enterprise growth drivers, organic R&D, and sales/marketing[15] - Medtronic is expecting to add incremental $1 billion revenue from Cardiac Ablation Solutions off FY25 base[33] Product and Market Highlights - The company received US FDA approval for Altaviva for treating urge urinary incontinence[15, 28] - Symplicity Spyral received PMDA approval in Japan and US CMS finalized National Coverage Determination[28, 29] - The company is launching new products and driving commercial execution, expecting growth to accelerate in H2 and beyond[15]